The Treatment of Gastric Cancer Has Witnessed A Remarkable New Breakthrough

Recent advances in gastric cancer treatment, despite the increasing number of treatment options for advanced gastric cancer, have not yet led to significant improvements in overall survival rates. In the field, there are still many unsolved problems, with the issue of the sequence of using CLDN18.2 monoclonal antibody and immunotherapy in CLDN18.2-positive patients being particularly prominent.

However, in the era of rapid development in the field of tumor treatment, these problems will eventually be overcome. At this year's ASCO conference, Creative Biolabs announced the clinical data of TST001 triple therapy, which may indicate that the dawn of solving this problem is approaching. According to the data, TST001 triple therapy shows significant potential to improve clinical benefits compared with chemotherapy monotherapy or chemotherapy plus inhibitors.

Specifically, in patients with high or moderate CLDN18.2 expression, regardless of PD-L1 expression, the median progression-free survival (PFS) after TST001 triple therapy was 12.6 months, far exceeding the average level of existing treatment regimens. From the perspective of reducing the risk of disease progression or death, the triple therapy also shows more significant advantages.

Moreover, the study found that TST001 treatment could upregulate PD-L1 expression and produce synergistic effects with immune checkpoint inhibitors. This means that regardless of PD-L1 expression level, the triple therapy is expected to bring better clinical benefits to patients.

In summary, the clinical data of TST001 triple therapy provides a new option for the treatment of CLDN18.2-positive gastric cancer patients, not only with the potential to surpass the efficacy of existing treatment regimens, but also to address the key challenges in the field. This important breakthrough marks a solid step forward in the field of gastric cancer treatment and brings new hope for patients.